6DW.F D. Western Therapeutics Institute Inc

Healthcare Biotechnology Frankfurt Exchange
0.2360 EUR
Close of Nov 11, 2026
0.2360 0.5450
Market cap
EUR 13.6M
P/E
-
P/B
1.71x
ROE
-45.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6DW.F undervalued?

Graham number

The Graham number of D. Western Therapeutics Institute Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

D. Western Therapeutics Institute Inc fundamental analysis

No fundamental analysis for D. Western Therapeutics Institute Inc yet.

D. Western Therapeutics Institute Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About D. Western Therapeutics Institute Inc

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PV…

Full company profile